Journals / Turkish Journal of Gastroenterology / 2005 / Cilt: 16 - Sayı: 1

Non-alkolik yağlı karaciğer hastalığında apoptoz ve fibrozis

Apoptosis and fibrosis in non-alcoholic fatty liver disesase

Pages
1–6
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In order to illuminate this context, this article focuses on the pathogenesis and possible new therapeutic options in nonalcoholic fatty liver disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nonalcoholic fatty liver disease is becoming an increasingly common medical problem in the developed countries which, unfortunately, still is associated with the lack of any effective treatment.
📊
Key Findings & Data:However, recent data favor a model in which a pathologically increased rate of hepatocytic apoptosis and the subsequent induction and upregulation of inflammation and fibrosis in the liver provide both a rationale for the pathogenesis of nonalcoholic fatty liver disease, as well as a clue for designing first effective therapeutic strategies.
💡
Conclusion & Impact:In order to illuminate this context, this article focuses on the pathogenesis and possible new therapeutic options in nonalcoholic fatty liver disease.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Apoptoz · Yağlı karaciğer · Enflamasyon

Abstract

Nonalcoholic fatty liver disease is becoming an increasingly common medical problem in the developed countries which, unfortunately, still is associated with the lack of any effective treatment. However, recent data favor a model in which a pathologically increased rate of hepatocytic apoptosis and the subsequent induction and upregulation of inflammation and fibrosis in the liver provide both a rationale for the pathogenesis of nonalcoholic fatty liver disease, as well as a clue for designing first effective therapeutic strategies. In order to illuminate this context, this article focuses on the pathogenesis and possible new therapeutic options in nonalcoholic fatty liver disease.

Özet

Özellikle gelişmiş ülkelerde giderek artan bir biçimde görülmekte olan alkole bağlı olmayan yağlı karaciğer hastalığı (NAFLD, Nonalcoholic fatty liver disease), etkin bir tedavisi bulunmayan ciddi bir tıbbi sorun olarak günümüzde karşımıza çıkmaktadır. Ancak, son dönemlerde yürütülen çalışmalar ile, hepatositlerde programlı hücre olumunun yani apoptozun patolojik bir biçimde arttığı gösterilmiş ve bunun sonucu olarak da, karaciğerde inflamasyonun indüklenerek fibrozun geliştiği ortaya konmuştur. Geliştirilen bu hastalık modeli alkole bağlı olmayan yağlı karaciğer hastalığı’nın hem patogenezini açıklığa kavuşturacak, hem de etkin tedavi stratejilerinin geliştirilmesine öncülük edecek niteliktedir. Bu derleme, sözkonusu bilgilerin ışığında, alkole bağlı olmayan yağlı karaciğer hastalığı’nın patogenezini irdelemekte ve olası tedavi opsiyonlarını gözden geçirmektedir.

🔖

Cite This Article

CANBAY, A., KİP, S. N., KAHRAMAN, A., GIESELER, R. K., NAYCI, A., GERKEN, G. (2005). Non-alkolik yağlı karaciğer hastalığında apoptoz ve fibrozis. Turkish Journal of Gastroenterology, Cilt: 16 - Sayı: 1, 1–6. https://ajindex.com/articles/410877

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45
  2. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74
  3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31
  4. Angulo P, Alba LM, Petrovic LM, et al. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004; 41: 943-9
  5. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a casecontrol study. Hepatology 2000; 32: 689-92
  6. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9
  7. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-94
  8. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8
  9. Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123: 1323-30
  10. Jaeschke H. Inflammation in response to hepatocellular apoptosis. Hepatology 2002; 35: 964-6
  11. Canbay A, Guicciardi ME, Higuchi H, et al. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J Clin Invest 2003; 112: 152-9
  12. Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004; 127: 1189-97
  13. Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003; 125: 437-43
  14. Savill J. Apoptosis in resolution of inflammation. Kidney Blood Press Res 2000; 23: 173-4
  15. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627-33
  16. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12
  17. Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology 1999; 29: 1-4
  18. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501
  19. Thornberry NA. Caspases: key mediators of apoptosis.